Identification
- Generic Name
- Abetimus
- DrugBank Accession Number
- DB06662
- Background
Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Nucleic Acid Based Therapies
Oligonucleotides - Synonyms
- Abetimus
Pharmacology
- Indication
Investigated for use/treatment in kidney disease and systemic lupus erythematosus.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Abetimus. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Abetimus. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Abetimus. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Abetimus. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Abetimus. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abetimus. Allogeneic processed thymus tissue The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Abetimus. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Abetimus. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Abetimus. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Abetimus. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Abetimus sodium F5Y7739G6U 169147-32-4 Not applicable - International/Other Brands
- Riquent
Categories
- ATC Codes
- L04AA22 — Abetimus
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P3UVQ22SHK
- CAS number
- 167362-48-3
References
- General References
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Autoimmune Disorder / Immunologic Diseases / Lupus Glomerulonephritis / Lupus Nephritis / Systemic Lupus Erythematosus (SLE) 1 3 Terminated Treatment Lupus Nephritis / Systemic Lupus Erythematosus (SLE) 1 2 Withdrawn Diagnostic Systemic Lupus Erythematosus (SLE) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at March 19, 2008 16:46 / Updated at February 21, 2021 18:52